Januvia (sitagliptin) is a prescription drug that’s used to treat type 2 diabetes in adults. The drug comes as an oral tablet. It’s usually taken once per day. Januvia is used in adults to treat type ...

Expert Rev Endocrinol Metab. 2008;3(6):691-697. Elimination of sitagliptin occurs primarily via renal excretion (79%) and involves active tubular secretion. Sitagliptin is a substrate for human ...

April 18 (UPI) --In comparing three classes of medication for type 2 diabetes, researchers found one class, which includes the drugs Onglyza, Janumet and Januvia, did not reduce the risk of death.

(Reuters) - Merck and Co's diabetes drug Januvia achieved the main goal of a long-awaited heart safety study, according to preliminary results released by the drugmaker on Monday, likely removing a ...

NEW YORK (Reuters) - Aggressive marketing of Merck & Co.'s new first-in-class diabetes drug Januvia has led to a strong launch, according to data compiled by ImpactRx Inc., a market research company ...

The Market Share for DPP-IV Inhibitors and GLP-1 Analogues Will Increase by 22 Percent Through 2019, According to Findings from Decision Resources BURLINGTON, Mass., Sept. 21 /PRNewswire/ -- Decision ...

Sitagliptin (Januvia™) is a new oral agent approved by the US FDA to treat Type 2 diabetes. This is the first approved agent in a new class of antihyperglycemics, dipeptidyl peptidase (DPP)-4 ...